Christopher G. Bunick, MD, PhD

Christopher Bunick, MD, PhD, shares his insights on the FDA approval of bemotrizinol and what the ingredient's properties mean for sun protection and cosmetic elegance.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

Dermatology Times' editor in chief highlights essential late-breaker data from AAD 2026, including upadacitinib, rezpegaldesleukin, icotrokinra, zasocitinib, envudeucitinib, sonelokimab, and more.

Dermatology Times' editor in chief highlights essential late-breakers from AAD 2026, including rademikibart, KT-621, nemolizumab, and delgocitinib.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.

Christopher Bunick, MD, PhD, and Almirall's Johnny Im discuss new data showing that tirbanibulin 1% ointment provides consistent efficacy, while expanded coverage is poised to improve patient access in the US.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

Dermatologists tailor seborrheic dermatitis care with shared decisions, steroid-sparing options, combo therapy, and flare-ready expectations.

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Dermatologists weigh rifamylast, JAK inhibitors and antifungals for long-term seborrheic dermatitis control, balancing efficacy, safety and access.

New rifamilast 0.3% foam shows fast, sustained seborrheic dermatitis clearing with high tolerability—plus tips for long-term maintenance.

Discover how rifamylast foam, a new FDA-approved PDE4 inhibitor, offers steroid-free relief for seborrheic dermatitis—calms itch, face-safe.

Discover how FDA-approved rifamylast foam targets PDE4 to calm seborrheic dermatitis—face-safe, steroid-free relief for itch and redness.

February highlights rare genetic skin diseases, shifting dermatology from supportive care to molecularly targeted therapies.

Rethink seborrheic dermatitis care: limit facial steroids, use antifungals wisely, and watch emerging barrier-safe targeted therapies.

Early seborrheic dermatitis treatment reduces inflammation, prevents worsening, and boosts quality of life; experts explain pediatric vs adult goals and mask-triggered flares.

This episode, titled Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden, features dermatology experts discussing the following critical questions: How might presentation of SD differ in various skin tones? What challenges do you encounter when diagnosing SD in patients with skin color? In your experience, what long-term complications arise when SD is inadequately treated or remains uncontrolled over time?

Seborrheic dermatitis varies by age, affects scalp and face, drives itching and stigma, and lowers quality of life—highlighting newer targeted treatments.

Experts discuss how seborrheic dermatitis can be distinguished from atopic dermatitis and psoriasis through clinical features and underlying immune patterns, highlighting the role of Th17/Th22-driven inflammation and barrier dysfunction in guiding more precise, targeted treatment strategies.

Experts discuss how seborrheic dermatitis arises from a multifactorial interplay of immune dysregulation, Malassezia yeast colonization, epidermal barrier impairment, and sebaceous gland activity, shaping its chronic nature and informing targeted treatment approaches.

The 2026 meeting emphasized integrating cutting-edge medical therapies with aesthetic strategies to address both disease control and quality of life.

The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with atopic dermatitis receive systemic corticosteroids.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Explore the latest dermatology trends for 2026, including innovative therapies for psoriasis, atopic dermatitis, and hair-loss advancements.

Explore the latest advancements in chronic spontaneous urticaria (CSU) therapies, including innovative treatments and patient-centered management strategies.